Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 4
2008 1
2009 1
2012 1
2013 1
2014 2
2015 3
2016 2
2017 6
2018 2
2019 3
2020 4
2021 5
2022 4
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Results by year

Filters applied: . Clear all
Page 1
Studying clonal dynamics in response to cancer therapy using high-complexity barcoding.
Bhang HE, Ruddy DA, Krishnamurthy Radhakrishna V, Caushi JX, Zhao R, Hims MM, Singh AP, Kao I, Rakiec D, Shaw P, Balak M, Raza A, Ackley E, Keen N, Schlabach MR, Palmer M, Leary RJ, Chiang DY, Sellers WR, Michor F, Cooke VG, Korn JM, Stegmeier F. Bhang HE, et al. Nat Med. 2015 May;21(5):440-8. doi: 10.1038/nm.3841. Epub 2015 Apr 13. Nat Med. 2015. PMID: 25849130
Burrow Ink Test for Scabies.
Rauwerdink D, Balak D. Rauwerdink D, et al. N Engl J Med. 2023 Aug 17;389(7):e12. doi: 10.1056/NEJMicm2216654. Epub 2023 Aug 12. N Engl J Med. 2023. PMID: 37578077 No abstract available.
SALL1 enforces microglia-specific DNA binding and function of SMADs to establish microglia identity.
Fixsen BR, Han CZ, Zhou Y, Spann NJ, Saisan P, Shen Z, Balak C, Sakai M, Cobo I, Holtman IR, Warden AS, Ramirez G, Collier JG, Pasillas MP, Yu M, Hu R, Li B, Belhocine S, Gosselin D, Coufal NG, Ren B, Glass CK. Fixsen BR, et al. Nat Immunol. 2023 Jul;24(7):1188-1199. doi: 10.1038/s41590-023-01528-8. Epub 2023 Jun 15. Nat Immunol. 2023. PMID: 37322178 Free PMC article.
[Spectrum of psoriatic conditions].
Pouw JN, Leijten EFA, Tekstra J, Balak DMW, Radstake TRDJ. Pouw JN, et al. Ned Tijdschr Geneeskd. 2019 Jul 29;163:D3936. Ned Tijdschr Geneeskd. 2019. PMID: 31361418 Dutch.
KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer.
Krall EB, Wang B, Munoz DM, Ilic N, Raghavan S, Niederst MJ, Yu K, Ruddy DA, Aguirre AJ, Kim JW, Redig AJ, Gainor JF, Williams JA, Asara JM, Doench JG, Janne PA, Shaw AT, McDonald Iii RE, Engelman JA, Stegmeier F, Schlabach MR, Hahn WC. Krall EB, et al. Elife. 2017 Feb 1;6:e18970. doi: 10.7554/eLife.18970. Elife. 2017. PMID: 28145866 Free PMC article.
Inhibitors that target the receptor tyrosine kinase (RTK)/Ras/mitogen-activated protein kinase (MAPK) pathway have led to clinical responses in lung and other cancers, but some patients fail to respond and in those that do resistance inevitably occurs (Balak et al., 2006; …
Inhibitors that target the receptor tyrosine kinase (RTK)/Ras/mitogen-activated protein kinase (MAPK) pathway have led to clinical responses …
Definitions of remission in psoriasis: a systematic literature review from the National Psoriasis Foundation.
Balak DMW, Perez-Chada LM, Guo LN, Mita C, Armstrong AW, Bell SJ, Gondo GC, Liao W, Merola JF. Balak DMW, et al. J Eur Acad Dermatol Venereol. 2022 Dec;36(12):2291-2300. doi: 10.1111/jdv.18477. Epub 2022 Sep 1. J Eur Acad Dermatol Venereol. 2022. PMID: 35924437 Review.
Most definitions included endpoints based on Psoriasis Area and Severity Index (PASI), such as PASI75 (n = 16 studies), PASI90 (n = 10), PASI100 (n = 10), and PASI of 0 (n = 3), and descriptive endpoints related to 'skin clearance' (n = 18). ...
Most definitions included endpoints based on Psoriasis Area and Severity Index (PASI), such as PASI75 (n = 16 studies), PASI90 (n …
International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis.
van Huizen AM, Menting SP, Gyulai R, Iversen L, van der Kraaij GE, Middelkamp-Hup MA, Warren RB, Spuls PI; SPIN MTX Consensus Survey Study Group; Schejtman AA, Egeberg A, Firooz A, Kumar AS, Oakley A, Foulkes A, Ramos AMC, Fougerousse AC, Carija A, Akman-Karakas A, Horváth B, Fábos B, Matlock BH, Claréus BW, Castro C, Ferrándiz C, Correa CC, Marchesi C, Goujon C, Gonzalez C, Maldonado-García C, Hong CH, Griffiths CEM, Vestergaard C, Echeverría CM, de la Cruz C, Conrad C, Törocsik D, Drvar DL, Balak D, Jullien D, Appelen D, Kim DH, de Jong EMGJ, El Gamal E, Laffitte E, Mahé E, Sonkoly E, Colombo EP, Vilarrasa E, Willaert F, Novoa FD, Handjani F, Valenzuela F, Vílchez-Márquez F, Gonzalez GO, Krisztián G, Damiani G, Krnjevic-Pezic G, Pellerano G, Carretero G, Hunter HJA, Riad H, Oon HH, Boonen HPJ, Moussa IO, García-Doval I, Csányi I, Brajac I, Turchin I, Grozdev I, Weinberg JM, Nicolopoulos J, Wells J, Lambert JLW, Ingram JR, Prinz JC, de Souza Sittart JA, Sanchez JL, Hsiao JP, Castro-Ayarza JR, Maul JT, van den Reek JMPA, Trcko K, Barber K, Reich K, Gebauer KA, Khobzei K, Maul LV, Massari LP, Fardet L, le Cleach L, Misery L, Chandrashekar L, Muresanu LI, Lecluse L, Skov L, Frez ML,… See abstract for full author list ➔ van Huizen AM, et al. JAMA Dermatol. 2022 May 1;158(5):561-572. doi: 10.1001/jamadermatol.2022.0434. JAMA Dermatol. 2022. PMID: 35353175
Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions.
Marshall AD, Willing AR, Kairouz A, Cunningham EB, Wheeler A, O'Brien N, Perera V, Ward JW, Hiebert L, Degenhardt L, Hajarizadeh B, Colledge S, Hickman M, Jawad D, Lazarus JV, Matthews GV, Scheibe A, Vickerman P, Dore GJ, Grebely J; Global HCV and HIV Treatment Restrictions Group. Marshall AD, et al. Lancet Gastroenterol Hepatol. 2024 Apr;9(4):366-382. doi: 10.1016/S2468-1253(23)00335-7. Epub 2024 Feb 15. Lancet Gastroenterol Hepatol. 2024. PMID: 38367631 Review.
Among 102 low-income and middle-income countries (LMICs), 89 (87%) had registered at least one HCV DAA therapy and 53 (52%) reimbursed at least one DAA therapy. Among all countries with DAA therapy reimbursement (n=109), 66 (61%) required specialist prescribing, eight (7%) …
Among 102 low-income and middle-income countries (LMICs), 89 (87%) had registered at least one HCV DAA therapy and 53 (52%) reimbursed at le …
40 results